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Juerg Schmidli, MD,a and Iris Baumgartner, MD,b Berne, Switzerland
Objective: The optimal revascularization strategy in diabetic patients with chronic critical limb ischemia (CLI) is unclear.
This study assessed the efficacy of tailored endovascular-first vs surgical-first revascularization stratified for the presence
of diabetes.
Methods: This prospective cohort study, with 1-year follow up, was conducted in a tertiary referral center in a consecutive
series of 383 patients (45.7% had diabetes) presenting 426 limbs with chronic CLI. Interventions were endovascular
(PTA cohort, 207 limbs) or surgical (SURG cohort, 85 limbs) revascularization. Conservatively treated patients without
revascularization (NON REVASC cohort, 108 limbs) were used as a reference. The main outcome measures were
sustained clinical success, defined as survival without major amputation or repeated target extremity revascularization
(TER), and a categoric upward shift in clinical symptoms according to the Rutherford classification.
Results: Sustained clinical success of revascularization was significantly better in nondiabetic patients (hazard ratio [HR],
0.48; 95% confidence interval [CI], 0.29 to 0.72; P  .001 [SURG cohort]; HR, 0.53; 95% CI, 0.35 to 0.78; P  .002
[PTA cohort]) compared with diabetic patients (HR, 0.78; 95% CI, 0.44 to 1.43, P  .45 [SURG cohort]; HR, 0.83;
95% CI, 0.55 to 1.27, P  .40 [PTA cohort]). Repeated TER significantly improved clinical success, which became
equivalent between diabetic and nondiabetic patients (HR, 1.02; 95% CI, 0.7 to 1.4). In multivariate analysis, treatment
success was not influenced bymode of initial revascularization, neither in diabetic nor in nondiabetic patients. Cumulative
1-year mortality was 30.4%, with a trend of increasedmortality in patients with diabetes (HR, 1.45; 95%CI, 0.98 to 2.17;
P  .064). Limb salvage rates were similar in treatment cohorts, also if stratified for diabetes (HR, 1.04; 95% CI, 0.62
to 1.75).
Conclusion: Diabetic patients with chronic CLI benefit from early revascularization. To achieve this benefit, multiple
revascularization procedures may be required, and close surveillance is therefore mandatory. Choice of initial revascu-
larization modality seems not to influence clinical success. ( J Vasc Surg 2007;45:751-61.)Diabetes mellitus is one of the major risk factors of
peripheral arterial occlusive disease (PAOD)1-3 and affects
the arterial tree in a centrifugal pattern.4,5 Its prevalence is
particularly high in patients with chronic critical lower limb
ischemia (CLI).6,7 Considering the dismal natural course
of CLI,8 there is no doubt that arterial revascularization
improves the prognosis, even in diabetic patients.9 In-
deed, current recommendations call for attempts of ar-
terial reconstruction in any patient with CLI if the 1-year
probability of survival and limb salvage can be estimated
at 25%.10,11
Many authors now consider percutaneous transluminal
angioplasty (PTA), with or without stenting, as the first-
line approach for CLI because results are similar to recon-
structive surgery even in the infrapopliteal segment and it
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doi:10.1016/j.jvs.2006.12.022potentially offers advantages such asminimal access trauma,
low infection rates, and shorter hospital stays.10,12-16
Surprisingly little is known about the impact of dia-
betes on the efficacy of either treatment modality in a
nonselected patient population with CLI.17,18 Data from
randomized coronary revascularization trials clearly show a
disadvantage of endovascular treatment for diabetic pa-
tients.19-21 It is unclear whether this finding is reflected by
peripheral arterial interventions, especially if small-calibre
vessels are treated. Recommendations are therefore contro-
versial,5,12,14,16,22,23 and the optimal treatment of diabetic
patients with CLI remains to be determined. Objective of
this study was to prospectively assess the efficacy of PTA or
reconstructive surgery as the first-line treatment for CLI in
patients with or without diabetes in a single-center cohort
study.
METHODS
All patients with chronic CLI presenting to the Swiss
Cardiovascular Center (SCVC), at the University Hospital
Berne, between January 1999 and June 2004 were pro-
spectively followed for 12months. Recorded patient details
included demographic characteristics, risk factors, clinical
presentation, imaging studies, treatment modality, and
prospective follow-up data. Approval of the responsible
Ethical Committee (Ministry of Health, Canton of Berne,
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study started. The study was conducted according to the
Declaration of Helsinki,24 and patients gave informed con-
sent before inclusion into the study.
Definition of CLI followed current consensus11,23: (1)
presence of ischemic rest pain for 2 weeks or ischemic
tissue loss associated with (2) an absolute ankle pressure
of 50 mm Hg or great toe pressure of 30 mm Hg.
Patients with acute limb ischemia were excluded.
Assessment of the peripheral circulation was performed
at baseline and at 2, 6, and 12 months, respectively. This
consisted of a complete noninvasive vascular work-up, in-
cluding measurements of systolic blood pressures of both
the anterior and posterior tibial arteries, calculation of
ankle-brachial index (ABI), and imaging studies consisting
of duplex scan, angiography, computed tomography an-
giography, or magnetic resonance angiography. Great toe
pressure measurements by photoplethysmography were
added in cases when arteries were considered incompressible
(ABI 1.15)25 or oscillometric readings showed poor pulsa-
tility despite absolute ankle pressures50 mmHg. Transcu-
taneous partial oxygen tissue pressures (tcpO2) of the forefoot
were also recorded in supine and sitting positions.
In view of advanced age and comorbidities of CLI
patients, a range of about 3 weeks around each scheduled
study visit was tolerated; however, patients were followed
up more frequently according to individual clinical needs.
Repeated imaging studies were limited to patients where
recurrent stenosis or occlusion or additional arterial lesions
were suspected clinically or hemodynamically. Experienced
vascular technicians performed all vascular laboratory mea-
surements. Grading of the severity of ischemia followed the
classification system proposed by Rutherford et al.26 Pa-
tients were not followed up systematically after end of the
study, but according to clinical needs.
All patients were evaluated on a case-by-case basis by a
dedicated multidisciplinary vascular board that included
interventional angiologists, radiologists, and vascular sur-
geons. This panel was established according to interna-
tional recommendations11 and had convened since 1998
for daily conferences. Departmental guidelines for optimal
revascularization were continuously adapted to recommen-
dations,11,23 and a strategy “to treat patients with chronic
CLI by endovascular means whenever technically possible
rather than to operate” was adopted from the beginning of
the recruitment period.
Although relative contraindications for endovascular
treatment, such as a long iliac artery or superficial femoral
artery (SFA) occlusions (especially if they started at the
origin of the SFA), heavily affected calf vessels, and heavily
calcified lesions, were more often operated on in the begin-
ning, advances in endovascular techniques changed the situa-
tion over time. In general, TransAtlantic Inter-Society Con-
sensus C and D lesions and obstructions spanning more than
a single anatomic level (ie, femoropopliteal, below the knee)
were not excluded from endovascular therapy.
The intervention decision was determined by clinical
presentation, urgency of therapy, general condition of thepatient, including presence of limiting comorbidities as well
as anatomic distribution and morphologic nature of vascu-
lar lesions, availability of autologous veins, and access for
endovascular therapy.27 The same panel was involved in treat-
ment decisions during follow-up for need for repeated or
delayed target extremity revascularizations (TER) and major
amputations. Decisions on repeated TER were invariably
based on vascular imaging in addition to clinical findings.
In cases of prohibitive lesion pattern, patient’s refusal,
or if the overall clinical situation suggested an expectant
attitude, CLI was handled conservatively by best medical
treatment, including analgesic, antibiotic and antiplatelet
and antithrombotic therapy, as well as lipid-lowering, anti-
hypertensive, and diabetes medications, and infrequently,
prostaglandins.3,27
Patients who underwent primary amputation owing to
irreversible ischemic damage were registered for descriptive
analysis but were excluded from analyses. Data sets with
missing baseline information, without follow-up, or patient
refusal were excluded from analysis.
Treatment cohorts. Patients were included into one
of the following cohorts according to the primary therapeutic
approach: SURG cohort, open revascularization by recon-
structive surgery; PTA cohort, endovascular revascularization
by PTA with or without stenting; or NON REVASC cohort,
conservative treatment without revascularization. Best medi-
cal therapy was applied equally to all treatment cohorts and
consisted of the previously mentioned pharmacologic treat-
ment. All treatment cohorts were called at 2, 6, and 12
months for the same follow-up visits.
Study end points. The primary efficacy end point of
the study was sustained clinical success,28 defined as sur-
vival without major amputation or repeated TERs, and
improvement of clinical symptoms according to Ruther-
ford et al,26 which is a categoric upward shift of at least one
clinical category for all categories except for baseline cate-
gory 5 (upward shift of at least 2 clinical categories), in
combination with hemodynamic improvement of either
ABI (0.1), toe pressure, or oscillometric reading. Second-
ary clinical success followed the same criteria but was not
censored for repeated TER. The secondary end points
analyzed were individual cumulative rates of all cause mor-
tality, limb salvage, repeated TER, and sustained clinical
improvement.
Definitions. The following definitions were used:
● Arterial hypertension was assumed when the measure-
ment of arterial blood pressure was 140 mm Hg
(systolic) or 90 mmHg (diastolic), or both, at least on
two different occasions, or if the patient was taking
antihypertensive medication.
● Hyperlipidemia was defined by a total serum choles-
terol level of 5 mmol/L, serum high-density li-
poprotein cholesterol level of 1 mmol/L, or serum
triglyceride level of 2 mmol/L. Hyperlipidemia was
also assumed if a patient was taking lipid-lowering
medication.
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levels 120 mg/dL, or a hemoglobin A1c level 6%.
The presence of diabetes mellitus was also assumed if
the patient was taking hypoglycemic medications.
● Current smoking habits were divided into either smok-
ing or nonsmoking.
● Renal insufficiency was defined by serum creatinine
levels 130 mol/L.
● The ABI calculation was performed by division of the
highest systolic arterial pressure reading of the tibial
arteries through systemic blood pressure. Tibial artery
incompressibility was assumed when ABI was 1.15
because this cutoff value has been reported to be
invariably associated with heavy continuous calcifica-
tion of tibial vessels.25
● Amputations were considered major and thus regis-
tered if performed above the ankle.
● Limb salvage was defined as absence of major amputa-
tion during the observation period and thus preserva-
tion of a functional lower extremity.
Statistical methods. Continuous and normally dis-
tributed variables are reported as mean  standard devia-
tion, and asymmetrically distributed variables as median
(range). Categoric variables are presented as numbers (per-
centages). Differences between continuous variables were
assessed by two-tailed unpaired t test if normally distrib-
uted, and by Mann Whitney U test if asymmetrically dis-
tributed. Differences of categoric variables were assessed by
the two-tailed Fisher exact test. A value of P  .05 was
considered to indicate statistical significance, except for
situations where the P value had to be adjusted according to
Bonferroni to keep the accepted  error at 5%, such as when
Table I. Demographic data of patients consisting of 383 p
Data* All (N 416) n (%) D
Female 176 (42.3)
Male 240 (57.7)
Age, years 75.5  10.9 (40.3-94.9) 75.
Blood pressure
Systolic 144  25
Diastolic 74  11
Arterial hypertension 312 (75.2)
Smoking 220 (53.0)
Renal insufficiency 115 (27.6)
Creatinine, mol/L 102 (27-757)
Dialysis 27 (6.6)
Hyperlipidemia 233 (56.1)
Cholesterol, mmol/L 5.05 (2.10-11.58)
HDL, mmol/L 4.11 (0.85-11.13)
Homocysteine, mol/L 17 (6-47)
Fibrinogen, g/L 4.00 (1.5-9.0)
Platelet inhibitor 217 (52.4)
Anticoagulation 122 (29.5)
*Continuous and normally distributed variables are reported as mean 
categoric variables numbers (percentages).
†All except 2 diabetic patients had adult onset diabetes (type II).
‡Two-tailed Fisher exact test.
§Mann-Whitney U test.more than two samples were compared.29 In these situa-tions, the Kruskal-Wallis test was used and the adjusted
values of P are especially indicated.
Clinical success rates and secondary end points were
assessed by cumulative outcome estimates according to
Kaplan-Meier30 as recommended by Rutherford et al.26
Patients were uncensored in the event of death, major
amputation, repeated TER, and whenever clinical improve-
ment was either never reached or lost. The bivariate assess-
ment of interdependency of diabetes and revasculariza-
tion modality on influencing outcome was performed by
applying log-rank tests. Statistical control of potentially
confounding factors was reached by stepwise multivariate
analysis (Cox proportional regression). Differences are ex-
pressed as hazard ratios (HRs) with 95% confidence
intervals (CIs). All time-to-event analyses were performed
according to the intention to treat. All analyses were per-
formed using the SPSS 12.0.1 OG software (SPSS Inc,
Chicago, Ill).
RESULTS
During the study period, 383 consecutive patients with
426 chronic critically ischemic limbs were treated at the
SCVC, a tertiary referral center for a population of about
1.1 million people, accounting for 2% to 5% of all patients
seen with PAOD during the same period. Ten data sets
(2%) were excluded from analysis owing to missing baseline
information because of patient’s refusal to undergo vascular
imaging (n  2) or any form of treatment (n  2),
withdrawal of informed consent (n  1), and lack of any
follow-up data owing to relocation to other cantons (n 3)
or countries (n 2).
Demographic information on the remaining 416 limbs
ts with 416 critically ischemic limbs
ic (n190) n (%) Nondiabetic (n  226) n (%) P
71 (37.4) 105 (46.5) .073†
119 (62.6) 121 (53.5)
0.1 (41.5-94.9) 75.6  11.5 (40.3-94.7) .47§
143  25 145  26 .66§
73  11 75  11 .25§
154 (81.5) 158 (69.9) .009‡
92 (48.7) 128 (56.6) .12‡
62 (32.6) 53 (23.5) .047‡
104 (54-723) 101.5 (27-757) .05§
13 (6.9) 14 (6.3) .84‡
103 (54.4) 130 (57.4) .58‡
.92 (2.10-10.83) 5.08 (2.42-11.58) .27§
.42 (0.85-10.60) 4.04 (1.71-11.13) .11§
17 (6-47) 18 (9-40) .89‡
4.2 (1.5-8.4) 3.86 (1.8-9.0) .097§
98 (51.6) 119 (53.1) .77‡
56 (29.5) 66 (29.5) 1†
rd deviation, asymmetrically distributed variables as median (range), andatien
iabet
4  1
4
4
standa(376 patients) are summarized in Table I. In 16 patients
Percu
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of CLI unsuitable for revascularization or advanced foot
necrosis with or without secondary infection. Treatment
decisions on the remaining 400 limbs are summarized in
Fig 1. In 108 cases, attempts at revascularization were
initially refused because revascularization deemed not im-
mediately necessary in 41, missing consent to any interven-
tion in 14, local disease considered to be inaccessible for
both surgery and PTA in 39, or only for PTA whilst unfit
for surgery in 6, or prevalent comorbidities in 8. Delayed
arterial revascularization was performed in 29 limbs after a
median of 49 days (mean, 82  80 days; range, 1 to 327;
cumulative 37.5%) because of change of mind about initial
refusal in 8, change of clinical situation in patients initially
deemed not urgent in 15, and improved general condition
either rendering open surgery possible in 4 or endovascular
therapy reasonable in 2.
Table II summarizes information on clinical presenta-
tion and hemodynamic findings, including Rutherford cat-
egories, ABI measurements, tcpO2, oscillometric readings,
arterial obstructive pattern, and treatment modalities.
Patients complied with follow-up visits very consis-
tently. Rates of missing follow-up were 3% at 2 months, 3%
at 6 months, and 4% at 12 months, and were evenly
distributed between treatment cohorts (P  .05 by the
Fisher exact test).
Primary efficacy end points. Arterial revasculariza-
Fig 1. Decision flow chart. PTA,tion, regardless of whether PTA or open surgery, wasassociated with a significantly higher sustained clinical suc-
cess rate at 1 year, with a higher amputation-free survival
associated with clinical improvement compared with con-
servative therapy alone in nondiabetic patients (P .0004),
but not in diabetic patients (P  .3; Fig 2, A). If repeated
TER was applied as needed, clinical success considerably
improved (P  .0014, Fig 2, B) and became equivalent
between diabetic and nondiabetic patients (HR, 1.02; 95%
CI, 0.7 to 1.4). In multivariate analysis, success was not
influenced by the mode of the initial revascularization,
neither in diabetic nor in nondiabetic patients. Delay of
arterial revascularization was associated with poorer out-
come than immediate revascularization. This difference was
statistically significant in nondiabetic patients (P  .003)
and showed a strong trend in diabetic patients (P  .056,
Fig 2, C).
In multivariate analysis of sustained clinical success,
advanced age and diabetes were independent predictors of
poor outcome. Immediate revascularization, regardless of
whether it was PTA or reconstructive surgery, was indepen-
dently associated with favorable outcome compared with
delayed revascularization or no revascularization (P  .01
for both). Presence of diabetes had no influence on second-
ary clinical success when repeated TER was included into
multivariate analysis. Table III summarizes the results of
multivariate outcome analyses on primary study end points.
Secondary end point analysis. During follow-up,
taneous transluminal angioplasty.100 patients died, for a calculated, cumulative 1-year mor-
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Table IV. Multivariate analysis showed age and renal insuf-
ficiency to be independent predictors of higher mortality,
and arterial revascularization of lower mortality. Diabetes
was associated with higher mortality as a trend but missed
statistical significance (HR, 1.45; 95% CI, 0.98 to 2.17;
P  .064).
Limb salvage rates during the first year of follow-up
were similar in all treatment cohorts (Fig 3), also if stratified
for diabetes (HR for major amputation in diabetic patients,
1.04; 95% CI, 0.62 to 1.75; P .89). Indeed, no indepen-
dent predictive risk factors for major amputations could be
identified in multivariate analyses. Exact rates for survival
and major amputations as well as clinical improvement are
summarized in Table V.
Cumulative early and late rates of repeated TER are
given in Table V. Repeated TERs were performed in both
Table II. Clinical, hemodynamic, and morphologic data o
treatment modality and diabetes
Data
SURG
(n  85) P*
Diabetes 25 (29.4)
Age, years 72.3  10.9 .78§
Clinical presentation .4
Rutherford 4 17 (20.0)
Rutherford 5 65 (76.5)
Rutherford 6 3 (3.5)
Hemodynamic presentation
ABI 0.41 (0.21-1.07) .31§
ABI not measurable, n 12 (14.0) .9‡
TcPO2 (mm Hg) 6 (1-52) .31
§
Nonpulsatile oscillometric reading 61 (72.6) .4
Distribution of revascularized lesions
Pelvic axis 23 (27.1) .43‡
Infrainguinal above knee 83 (97.6) .9‡
Infrainguinal below knee 58 (68.2) .13‡
PTA data
Primary technical success
Stent
Surgery data
Y-prosthesis 5 (5.9) .9‡
Common femoral endarterectomy 5 (5.9) .15‡
Crossover bypass 5 (5.9) .9‡
Bypass above knee 29 (34.1) .19‡
Bypass below knee 49 (57.6) .19‡
Conduit materials .37
Autologous vein 41 (52.6)
Synthetic graft 35 (44.9)
Biograft 2 (2.6)
Bypass in history on same leg 14 (17) .34‡
SURG, Surgical-first cohort; PTA, (percutaneous transluminal angioplasty) e
ankle-brachial index; TcPO2, transcutaneous oxygen pressure.
Continuous and normally distributed variables are reported as mean standa
variables numbers (percentages)
*P value for diabetes.
†P value for cohorts. Values in brackets indicate adjusted significance levels
‡Two-tailed Fisher test.
§Mann-Whitney test.
Pearson 2 test.
¶Kruskal-Wallis test.PTA and SURG cohorts significantly more often in diabeticpatients than in nondiabetic patients (HR, 1.64; 95% CI,
1.15 to 2.33; P  .007). Similarly, an advanced stage of
PAOD was independently associated with higher rates of
repeated TER (HR, 1.85; 95% CI, 1.27 to 2.7; P  .002).
In the NON REVASC cohort, delayed revascularizations
were performed in similar frequency in patients with and
without diabetes. Distributions of repeated and delayed
TER are depicted in Fig 1.
Primary amputation. Mean age of those patients (6
women, 10 men) undergoing primary amputation, and
therefore not included in the analysis, was 80 years
(range, 52 to 94 years). All were categorized as having
Rutherford category 6 severity of PAOD. Three patients
(19%) had infectious gangrene, five (31%) were diabetic,
and 8 (50%) were heavy smokers. Thirteen patients had
an amputation limited to below the knee, and three
nondiabetic patients required primary amputation above
ated patients at first presentation with stratification for
PTA
 207) P*
NON REVASC
(n  108) P* P†
(57.5) 41 (38.0) .0001¶ [.017]
.1  9.7 .009§ 74.4  12.1 .24§ .002¶ [.017]
.23 .06‡ .2¶ [.017]
(14.5) 24 (22.2)
(84.5) 84 (77.8)
(1.0) —
(0.15-1.47) .64§ 0.44 (0.17-1.18) .81§ .028¶ [.017]
(32.0) .0001‡ 34 (31.0) .21‡ .005¶ [0.017]
(1-64) .28§ 9 (1-52) .42§ .18¶ [0.017]
(56.7) .32 70 (66.7) .2 .027¶ [0.017]
(14.5) .69‡ .018‡
(71.0) .54‡ .0001‡
(59.4) .09‡ .16‡
(94.7) .53‡
(10.1) .9‡
ascular-first cohort;NONREVASC, best medical therapy only cohort;ABI,
iation, asymmetrically distributed variables as median (range), and categoric
p  error at 5% according to Bonferroni.f tre
(n
119
77
30
175
2
0.45
67
5
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30
147
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196
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This prospective cohort study illustrates the clinical
outcome of endovascular-first vs surgical-first revasculariza-
tion in 383 consecutive patients with chronic CLI stratified
for the presence of diabetes. The key finding was that
diabetic patients with CLI could benefit from revascular-
ization, regardless of the technique used. To achieve this
benefit, however, multiple revascularization procedures
may be required, and it was shown that clinical outcome
can be improved to the same degree as in nondiabetic
Fig 2. Cumulative outcome estimates of primary efficacy
and diabetes by log-rank test. NON REVASC, Best me
(percutaneous transluminal angioplasty), endovascular-fi
surgical-first therapy compared with best medical therap
major amputation or repeated target extremity revascu
according to Rutherford et al.26 B, Secondary clinical su
with best medical therapy. Secondary clinical success was
clinical symptoms according to Rutherford et al26 allow
Table III. Multivariate comparison of clinical success rela
including stratification for diabetes
Adjusted relat
Risk ratio (95% C
Sustained clinical success†
Overall 0.59 (0.41-0.84
Diabetic patients 0.78 (0.44-1.43
Nondiabetic patients 0.48 (0.29-0.72
Secondary clinical success†
Overall 0.34 (0.22-0.51
Diabetic patients 0.39 (0.20-0.79
Non-Diabetic patients 0.29 (0.17-0.49
Secondary clinical success (including
delayed revascularizations)
Overall 0.53 (0.35-0.81
Diabetic patients 0.58 (0.28-1.19
Nondiabetic patients 0.47 (0.28-0.81
PTA, percutaneous transluminal angioplasty.
*Adjusted for age, sex, Rutherford-category at presentation, smoking statu
†No differences were found between PTA and SURG cohorts after multivar
interval, 0.64 to 1.25; P  .5).
Table IV. Causes of death (percentage of patients
included)
Cause of death n (%)
Cardiogenic (HF, MI) 35 (9.1)
Renal failure 9 (2.3)
Multiorgan failure 5 (1.3)
Pulmonary embolism 3 (0.8)
Respiratory failure (pneumonia) 8 (2.2)
Stroke 4 (1.0)
Carcinoma 7 (1.8)
Sepsis 9 (2.3)
Unknown 20 (5.2)
HF, Heart failure; MI, myocardial infarction.cular-first or surgical-first therapy compared with best medicalpatients by means of close follow-up and timely repetition
of TER as needed.
Diabetes is the most important risk factor for PAOD
apart from smoking.5 Its prevalence in symptomatic forms
of PAOD has been estimated at 20%,31 and was 13% in the
overall patient population treated for PAOD in the SCVC
during the study period. In contrast, estimates in chronic
CLI are 27% to 76%,10,13,14,17,32,33 well in accordance with
our finding of 45.7% diabetic patients. Diabetic patients
tend to have an accelerated form of atherosclerosis and
show faster progression of intimal hyperplasia at anastomo-
ses or angioplasty sites. The consequences are earlier and
higher rates of restenoses, which become even more pro-
nounced in vessels with a smaller calibre.4-7 This renders
diabetes one of the key factors to be observed when choos-
ing the adequate treatment strategy for a patient with CLI.
The influence of diabetes on vascular interventions has
been impressively shown on coronary artery disease (CAD).
In the Bypass Angioplasty Revascularization Investigation
(BARI) trial, diabetic patients with multivessel disease had
a significantly higher cardiac mortality up to 7 years after
percutaneous transluminal coronary angioplasty compared
with coronary artery bypass grafting.20 A meta-analysis
confirmed this finding, although the difference faded after
6.5 years.19 It is not known whether this unfavorable
y end points with bivariate analysis of treatmentmodality
therapy only cohort; SURG, surgical-first cohort; PTA
hort.A, Sustained clinical success of endovascular-first or
stained clinical success was defined as survival without
tions (TERs), and improvement of clinical symptoms
 of endovascular-first or surgical-first therapy compared
ed as survival without amputation, and improvement of
peated TERs. C, Secondary clinical success of endovas-
o best medical therapy (NON REVASC cohort)
k of surgery* Adjusted relative risk of PTA*
P Risk ratio (95% CI) P
.003 0.65 (0.50-0.86) .002
.450 0.83 (0.55-1.27) .400
.001 0.53 (0.35-0.78) .002
.001 0.38 (0.28-0.51) .001
.009 0.5 (0.32-0.78) .002
.001 0.29 (0.18-0.45) .001
.001 0.58 (0.42-0.79) .001
.140 0.72 (0.44-1.16) .170
.006 0.48 (0.30-0.75) .002
l insufficiency, hypertension, and hyperlipidemia.
justment for risk factors (relative risk of SURG cohort, 0.9, 95% confidencestud
dical
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April 2007758 Dick et alreaction to angioplasty is paralleled in diabetic patients
treated for PAOD, especially in chronic CLI, with often
small-calibre multivessel disease showing some similarities
with symptomatic CAD.
Only a few studies have investigated the impact of
diabetes on revascularization in consecutive, nonselected
patient populations with chronic CLI,17 and conflicting
data have prevented the establishment of accepted guide-
lines.5 Some authors remain sceptical about whether dia-
0 92 184 276 368
days
0.0
0.2
0.4
0.6
0.8
1.0
L
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P
c
Non-Diabetic Patients (n=215)
72.5%
84.6%
82.1%
No at risk (days) 0 92 184 276 368 N
NON REVASC 67 47 39 35 30
SURG 60 48 43 35 33
PTA 88 69 62 52 49
Log rank test SURG vs NON REVASC PTA vs NON REVASC SURG vs
P-value P= .207 P= .327 P= .6
Fig 3. Cumulative limb salvage estimates over one yea
NON REVASC, Best medical therapy only cohort; SU
angioplasty) endovascular-first cohort.
Table V. Kaplan Meier risk estimates for survival, major a
sustained clinical improvement at the 30-day and 1-year fo
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arterial revascularization, and the indication should be re-
strictive if the patient’s compliance or circumstances rule
out close follow-up and secondary interventions as needed.
However, with clinical implementation of close surveillance
and aggressive reintervention if needed, differences in clin-
ical success were no longer observed between diabetic and
nondiabetic patients. Neither modality of first nor of sub-
sequent revascularization influenced outcome, which is
consistent with series that show equivalent results of PTA
and surgery.17,33
The Bypass Versus Angioplasty in Severe Ischemia of the
Leg (BASIL) trial compared surgery-first and angioplasty-first
treatment for severe limb ischemia in a prospective, ran-
domized, controlled multicenter trial.33 In that highly se-
lected patient population—about 30% of patients qualified
for randomization—neither approach was superior to the
other. The mean age of patients and prevalence of diabetes
were similar to our series. Rates of mortality and amputation-
free survival at 1 year were almost identical to our PTA and
SURG cohorts (20% and 70%, respectively), and no clear
cut advantage of one or the other treatment modality was
observed even as the ideal treatment modality was chosen
individually, indicating that interventional treatment must
be considered at least equivalent to surgical reconstruction
in the therapy of severe lower limb ischemia.
In the BASIL trial, rate of repeated TER was signifi-
cantly higher in the angioplasty-first arm. After multivariate
adjustment, we could not reproduce this finding in our
series. The presence of diabetes was independently associ-
ated with a statistically significant higher rate of repeated
TER, however, reflecting the higher incidence of early
restenosis in diabetic patients.7 Of interest was that repeti-
tion of TER improved clinical success in diabetic patients
not only significantly but also to the same level as in
nondiabetic patients. Furthermore, the outcome of all pa-
tients was significantly better after immediate revasculariza-
tion than after delayed revascularization, as shown in Fig 2.
Rates of repeated TER and their distribution on PTA and
surgery were very similar to findings in the BASIL trial
(Fig 1).
One of the principal problems of comparing results of
surgery and PTA in chronic CLI is the vast heterogeneity of
end points used in the literature. Validation of therapy
depends on the definition of treatment success. Isolated or
combined limb salvage or mortality rates are investigated in
most surgical series, whereas patency rates are assessed in
most endovascular series. None of these measures reflect
patients’ quality of life during their remaining lifetime.
Indeed, from a patient’s perspective, it certainly does not
seem sufficient just to postpone amputation until after
death.35 Clinical success, rather, depends on survival with-
out major amputation (ie, preservation of a functional
lower limb), but only if associated with symptomatic im-
provement, desirably, without repetition of an interven-
tion.
A composite end point combining these parameters
therefore was chosen to compare clinical success in thedifferent treatment cohorts in our series. The strictness of
this approach may explain the seemingly poor treatment
results, but reflects the real-life outlook of individual pa-
tients, as shown by others.15 Individually comparing mor-
tality, major amputation, or repeated TER, our results are
well in accordance with other series.15,18,33 Comparing
cumulative outcome data for each of the individual end
point components (Table V, Fig 2) reveals the predomi-
nant influence of clinical improvement, an important mea-
sure that has seldom been included in other series. How-
ever, the importance of this primary functional outcome
measure has been emphasized in a recent expert’s consensus
document on reporting outcomes of endovascular treat-
ment.28
Overall mortality in our series was 30% at 1 year, which
reflects the poor prognosis of patients with chronic CLI and
is well in accordance with the literature.10,13,15 Most deaths
were due to cardiovascular events (39%) or pulmonary and
generalized infections (17%). In 20% of our patients, the
cause of death was either not sought (patients who died at
home or in nursing homes) or could not be revealed.
Survival was seemingly improved by arterial revascular-
ization. This has often been claimed to be due to lower
amputation-related death and more rapid ambulation after
revascularization. Because the decision for revasculariza-
tion was operator dependent, there might have been a
relevant selection bias for less aggressive revascularization
in high-risk patients prone for a higher mortality in our
series.
One striking finding, after adjustment for risk factors,
was that we did not find an independent influence of
revascularization on isolated limb salvage rates. The same
finding is depicted in the bivariate analysis in Fig 3. Others
have also made this observation.17,32 Bertele et al32 found
no influence of revascularization on limb salvage in a large
epidemiologic study of 1560 CLI patients. The most likely
explanation is the composition of our NON REVASC
cohort, which included patients suitable for reconstruction
and also those who either initially declined an invasive
treatment or in whom reconstruction was not considered
urgently necessary. This explains the nearly 40% of patients
with delayed revascularization who were retained in the
NON REVASC cohort for the purpose of an intention-to-
treat analysis.
Conversely, it is important to note that patients with
unsalvageable ischemic limbs were not included in our
analysis because they constitute a subset of CLI patients
with no other option than amputation. Their prevalence
was very low in our series, at 4% compared with 16% to 19%
in other series,8,11,36 probably because patients with obvi-
ously unsalvageable limbs have already undergone amputa-
tion in primary or secondary health care centers in a dense
health care system such as exists in central Europe. As a
result, together with exclusion of delayed revasculariza-
tions, this would have increased the 1-year amputation rate
to about 50% in theNONREVASC cohort, as is commonly
reported.8,23 Remarkably, the presence of diabetes did not
constitute an independent risk factor for amputation, an
JOURNAL OF VASCULAR SURGERY
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were excluded from analysis16,17,32,37 or when outcome of
unreconstructable CLI was studied.8
Limitations. Assignment of treatment in this con-
trolled, prospective cohort study was based on clinical
judgement, rather than on randomization; hence, all disad-
vantages of nonrandomized outcome studies are possibly
present. Conversely, randomization of a seemingly homo-
geneous patient population to treatment modalities that
essentially address different lesion pattern creates an impor-
tant ethical dilemma. In case of chronic CLI, either only
patients with lesion pattern equally suitable for both endo-
vascular and surgical revascularization are included (70% of
patients had to be excluded in the BASIL trial), thereby
possibly creating rather than preventing an important se-
lection bias, or randomization of unselected patients to
unsuitable and possibly harmful treatment must be ac-
cepted. Thus, even results from randomized controlled
trials cannot be easily translated to the general population,
and it is at least doubtful whether another randomized
controlled trial will be performed focusing in more depth
on subgroups of patients with chronic CLI.
The declared aim in the present series was to investigate
a representative sample of patients with chronic CLI, ques-
tioning whether diabetes influences clinical outcome in
patients with an individually tailored revascularization strat-
egy within a dedicated vascular center. It is remarkable that
results from our series were almost identical to the main
results of the BASIL trial despite completely different lim-
itations in methodology. From an evidence-based perspec-
tive, this finding is very reassuring since the validity of the
conclusions is corroborated from the other side.
Consistency in the decision-making process regarding
treatment assignment can be regarded as one of the most
critical issues in any nonrandomized outcome study. Con-
sensus in the present series was sought for every individ-
ual patient in a dedicated multidisciplinary vascular board,
and the involved consultants did not change during the
study period. Advances in endovascular materials and
techniques,14,15 however, increased the probability of
patients—especially diabetic patients—being assigned to
the PTA cohort over time. Comparing first and second part
of the study period, rates of endovascular revascularization
increased from 47% to 58%, whereas assignment to surgical
revascularization decreased from 25% to 17%. This progress
has also been described by others10,38 and highlights an-
other typical limitation of observational cohort studies in
fields with rapidly evolving technologies.
Although clinical presentation in terms of Rutherford
classification and hemodynamic assessment was very com-
parable, the distribution of arterial lesions differed consid-
erably between treatment cohorts (Table II). As expected,
surgically treated patients had a higher prevalence of mul-
tilevel disease because of higher occurrence of pelvic axis
and suprapopliteal disease, whereas distribution of arterial
lesions in the infrapopliteal segment was alike between the
SURG and PTA cohorts.As in other series, diabetic patients were assigned to
PTA significantly more often17 and were therefore under-
represented in the other treatment cohorts. Diabetic pa-
tients often have comorbidities that make minimally inva-
sive treatment modalities look more favorable. Concerns
about impaired healing of surgical wounds, increased risks
of infection, or silent CAD are important factors to refuse
surgery. In line with experiences of our own group and of
others,14,15 infrapopliteal disease was not considered to be
a contraindication for endovascular treatment, not even in
diabetic patients.
The uneven distribution of diabetes probably did not
influence the results, because most demographic character-
istics, distribution of risk factors, and lesion characteristics
were widely comparable between diabetic and nondiabetic
patients, apart from a significant association of hyperten-
sion and renal insufficiency with diabetes (Tables I and II).
For analysis, these differences were statistically controlled
by multiple regression analysis.
CONCLUSION
The study confirms the poor prognosis of chronic CLI,
with diabetes being one of the major risk factors. Revascu-
larization should be intended without delay in both nondi-
abetic and diabetic patients. Clinical outcome is improved,
regardless of endovascular-first or surgical-first revascular-
ization, as long as treatment is individually tailored to the
patient and his or her vascular morphology. To achieve
long-term benefit, however, multiple revascularization pro-
cedures may be required in diabetic patients, and a dedi-
cated interdisciplinary surveillance program is mandatory.
We thank Jolanda Vögele, RN, for assistance in data
preparation, and Brigitta Gahl, MSC, for assistance in sta-
tistical analysis.
AUTHOR CONTRIBUTIONS
Conception and design: FD, ND, JS, IB
Analysis and interpretation: FD, ND, AG, JS, IB
Data collection: FD, ND, AG, MH, IB
Writing the article: FD, ND
Critical revision of the article: AG, MH, JS, IB
Final approval of the article: FD, ND, AG, MH, JS, IB
Statistical analysis: FD, ND, IB
Obtained funding: Not applicable
Overall responsibility: IB
FD and ND contributed equally to this work.
REFERENCES
1. Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabe-
tes. J Am Coll Cardiol 2006;47:921-9.
2. Reynolds K, He J. Epidemiology of the metabolic syndrome. Am JMed
Sci 2005;330:273-9.
3. Diehm C, Diehm N. Non-invasive treatment of critical limb ischemia.
Curr Drug Targets Cardiovasc Haematol Disord 2004;4:241-7.
4. Diehm N, Shang A, Silvestro A, Do DD, Dick F, Schmidli J, et al.
Association of cardiovascular risk factors with pattern of lower limb
atherosclerosis in 2659 patients undergoing angioplasty. Eur J Vasc
Endovasc Surg 2006;31:59-63.
JOURNAL OF VASCULAR SURGERY
Volume 45, Number 4 Dick et al 7615. American Diabetes Association. Peripheral arterial disease in people
with diabetes. Diabetes Care 2003;26:3333-41.
6. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis:
epidemiology, pathophysiology, and management. JAMA 2002;287:
2570-81.
7. Jude EB,Oyibo SO, Chalmers N, Boulton AJ. Peripheral arterial disease
in diabetic and nondiabetic patients: a comparison of severity and
outcome. Diabetes Care 2001;24:1433-7.
8. Lepantalo M, Matzke S. Outcome of unreconstructed chronic critical
leg ischaemia. Eur J Vasc Endovasc Surg 1996;11:153-7.
9. Ebskov LB, Schroeder TV, Holstein PE. Epidemiology of leg amputa-
tion: the influence of vascular surgery. Br J Surg 1994;81:1600-3.
10. Nasr MK, McCarthy RJ, Hardman J, Chalmers A, Horrocks M. The
increasing role of percutaneous transluminal angioplasty in the primary
management of critical limb ischaemia. Eur J Vasc Endovasc Surg
2002;23:398-403.
11. Second European Consensus Document on chronic critical leg isch-
emia. Eur J Vasc Surg 1992;6(suppl A):1-32.
12. Faglia E, Dalla Paola L, Clerici G, Clerissi J, Graziani L, et al. Peripheral
angioplasty as the first-choice revascularization procedure in diabetic
patients with critical limb ischemia: prospective study of 993 consecu-
tive patients hospitalized and followed between 1999 and 2003. Eur J
Vasc Endovasc Surg 2005;29:620-7.
13. Danielsson G, Albrechtsson U, Norgren L, Danielsson P, Ribbe E,
Thorne J, et al. Percutaneous transluminal angioplasty of crural arteries:
diabetes and other factors influencing outcome. Eur J Vasc Endovasc
Surg 2001;21:432-6.
14. SoderHK,ManninenHI, Jaakkola P,Matsi PJ, RasanenHT,KaukanenE,
et al. Prospective trial of infrapopliteal artery balloon angioplasty for critical
limb ischemia: angiographic and clinical results. J Vasc Interv Radiol
2000;11:1021-31.
15. Balmer H, Mahler F, Do DD, Triller J, Baumgartner I. Balloon angio-
plasty in chronic critical limb ischemia: factors affecting clinical and
angiographic outcome. J Endovasc Ther 2002;9:403-10.
16. Hynes N,Mahendran B,Manning B, Andrews E, CourtneyD, Sultan S.
The influence of subintimal angioplasty on level of amputation and limb
salvage rates in lower limb critical ischaemia: a 15-year experience. Eur
J Vasc Endovasc Surg 2005;30:291-9.
17. Awad S, Karkos CD, Serrachino-Inglott F, Cooper NJ, Butterfield JS,
Ashleigh R, et al. The impact of diabetes on current revascularisation
practice and clinical outcome in patients with critical lower limb isch-
aemia. Eur J Vasc Endovasc Surg 2006;32:51-9.
18. Bailey CM, Saha S, Magee TR, Galland RB. A 1 year prospective study
of management and outcome of patients presenting with critical lower
limb ischaemia. Eur J Vasc Endovasc Surg 2003;25:131-4.
19. Hoffman SN, TenBrook JA, Wolf MP, Pauker SG, Salem DN, Wong
JB. Ameta-analysis of randomized controlled trials comparing coronary
artery bypass graft with percutaneous transluminal coronary angio-
plasty: one- to eight-year outcomes. J Am Coll Cardiol 2003;41:1293-
304.
20. Influence of diabetes on 5-year mortality and morbidity in a random-
ized trial comparing CABG and PTCA in patients with multivessel
disease: the Bypass Angioplasty Revascularization Investigation (BARI).
Circulation 1997;96:1761-9.
21. Weintraub WS, Stein B, Kosinski A, Douglas JS Jr, Ghazzal ZM, Jones
EL, et al. Outcome of coronary bypass surgery versus coronary angio-
plasty in diabetic patients with multivessel coronary artery disease. J Am
Coll Cardiol 1998;31:10-9.22. Pomposelli FB Jr, Marcaccio EJ, Gibbons GW, Campbell DR, Freeman
DV, Burgess AM, et al. Dorsalis pedis arterial bypass: durable limb
salvage for foot ischemia in patients with diabetes mellitus. J Vasc Surg
1995;21:375-84.
23. Dormandy JA, Rutherford RB. Management of peripheral arterial
disease (PAD). TASC Working Group. TransAtlantic Inter-Society
Concensus (TASC). J Vasc Surg 2000;31:S1-S296.
24. World Medical Association Declaration of Helsinki as amended by the
48th World Medical Assembly, October, 1996. Available at: http://
www.expertiseireland.com/pdfs/WMAHelsinki.pdf. Accessed Sep 16,
2006.
25. Emanuele MA, Buchanan BJ, Abraira C. Elevated leg systolic pressures
and arterial calcification in diabetic occlusive vascular disease. Diabetes
Care 1981;4:289-92.
26. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S,
et al. Recommended standards for reports dealing with lower extremity
ischemia: revised version. J Vasc Surg 1997;26:517-38.
27. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin
JL, et al. ACC/AHA guidelines for the management of patients with
peripheral arterial disease (lower extremity, renal, mesenteric, and ab-
dominal aortic): executive summary. J Am Coll Cardiol 2006;47:1239-
312.
28. Diehm N, Baumgartner I, Jaff M, Do DD, Minar E, Schmidli J, et al. A
call for uniform reporting standards in studies assessing endovascular
treatment for chronic ischemia of lower limb arteries. Eur Heart J 2007;
in press.
29. Bland JM, Altman DG. Multiple significance tests: the Bonferroni
method. BMJ 1995;310:170.
30. Kaplan EL, Meier P. Nonparametric estimation from incomplete
observations. J Am Stat Ass 1958;53:457-81.
31. Murabito JM, D’Agostino RB, Silbershatz H, Wilson WF. Intermittent
claudication. A risk profile from The Framingham Heart Study. Circu-
lation 1997;96:44-9.
32. Bertele V, Roncaglioni MC, Pangrazzi J, Terzian E, Tognoni EG.
Clinical outcome and its predictors in 1560 patients with critical leg
ischaemia. Chronic Critical Leg Ischaemia Group. Eur J Vasc Endovasc
Surg 1999;18:401-10.
33. AdamDJ, Beard JD, Cleveland T, Bell J, Bradbury AW, Forbes JF, et al.
Bypass versus angioplasty in severe ischaemia of the leg (BASIL):
multicentre, randomised controlled trial. Lancet 2005;366:1925-34.
34. Gutteridge W, Torrie EP, Galland RB. Cumulative risk of bypass,
amputation or death following percutaneous transluminal angioplasty.
Eur J Vasc Endovasc Surg 1997;14:134-9.
35. Bosiers M, Deloose K, Verbist J, Peeters P. Percutaneous transluminal
angioplasty for treatment of “below-the-knee” critical limb ischemia:
early outcomes following the use of sirolimus-eluting stents. J Cardio-
vasc Surg 2006;47:171-6.
36. Thompson MM, Sayers RD, Varty K, Reid A, London NJM, Bell PRF.
Chronic critical leg ischaemia must be redefined. Eur J Vasc Surg
1993;7:420-6.
37. Pomposelli FB, Kansal N, Hamdan AD, Belfield A, Sheahan M,
Campbell DR, et al. A decade of experience with dorsalis pedis artery
bypass: analysis of outcome in more than 1000 cases. J Vasc Surg
2003;37:307-15.
38. Kudo T, Chandra FA, Kwun WH, Haas BT, Ahn SS. Changing pattern
of surgical revascularization for critical limb ischemia over 12 years:
endovascular vs. open bypass surgery. J Vasc Surg 2006;44:304-13.Submitted Sep 16, 2006; accepted Dec 11, 2006.
